Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Diovan/Co-Diovan

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Diovan/Co-Diovan was produced by Novartis.

FDA approves Takeda antihypertensive

Phase III clinical studies of the angiotensin II receptor blocker (ARB) found that it was more effective at lowering blood pressure than the highest approved doses of Novartis' Diovan (valsartan) or

Takeda files combination blood pressure drug

Phase III clinical studies of azilsartan medoxomil on its own found that it was more effective at lowering blood pressure than Novartis' Diovan (valsartan) or Benicar.

Novartis blood pressure drug approved

Novartis launched the drug in the US in 2007 as a more effective follow-up to its blood pressure drug Diovan (valsartan), which is due to go off-patent in 2012.

Novartis to lay off 1,400 US sales reps

Among the major Novartis products that are facing patent expiration in the relatively near future are the hypertension drug Diovan (losartan) and the Alzheimer's disease drug Exelon (rivastigmine), both of

New launches see strong Q3 for Novartis

The company's biggest selling drugs were Gleevec/Glivec (imatinib mesylate), which took in $1.02bn and hypertension drug Diovan (valsartan) which increased sales by 2 per cent to $1.48bn.

[ Previous 5 results ] 3 4 5 6 7 8 9 10 11 12 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

Peter Howarth
Exploring the potential of eosinophils
GSK’s Peter Howarth talks about the emerging research that suggests there is a varied role for eosinophils...
white house
Eliminating pharmaceutical rebates, is this déjà vu?
By Andrew Parece and Matthew Majewski...
Patients are ready to embrace decentralised clinical trials, are you?
Traditional clinical trial designs simply can’t withstand the impact of COVID-19. While before the pandemic, some in clinical research were beginning to adopt virtual components, the move towards designing hybrid...

Infographics